Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

Phase 2 Completed 23 enrolled Kubota Vision Inc.

RandomizedParallel-groupQuadruple-blindTreatment

This is a pharmacodynamics study of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease.

Evaluation	Drug	Modality	Dose	Route
Subject	Emixustat	Small molecule	2.5 mg	Oral
Subject	Emixustat	Small molecule	5 mg	Oral
Subject	Emixustat	Small molecule	10 mg	Oral